Drug intelligence / Profile preview

Rellidep

Development stage: Phase 3
Lead developer: University of Toronto
Administration: Oral

Overview

Rellidep is a biological isolate (BI) that has been investigated for its antidepressant effects in major depressive disorder. It is hypothesized to contain mood-altering ingredients. An open-label pilot study conducted by the University of Toronto demonstrated positive effects on mood and well-being, with a significant decrease in Hamilton Depression Rating Scale (HAM-D) scores. The drug is administered orally.

Other names: Biological IsolateBTI

Beyond the preview

Go deeper on Rellidep.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rellidep.

Explore the full profile